The phrase "aggressive thyroid" is correct and usable in written English.
It can be used in a medical context to describe a thyroid condition that is overactive or producing excessive hormones.
Example: "The patient was diagnosed with an aggressive thyroid, leading to symptoms of hyperthyroidism."
Alternatives: "hyperactive thyroid" or "overactive thyroid".
We previously demonstrated that nuclear and cytoplasmic accumulation of the intracellular domain (Ep-ICD) of epithelial cell adhesion molecule (EpCAM) accompanied by a reciprocal reduction of its extracellular domain (EpEx), occurs in aggressive thyroid cancers.
Notably, our earlier report in thyroid cancers demonstrated a strong association between nuclear accumulation of Ep-ICD and a reduced membranous EpEx localization as well as shortened overall survival, suggesting the potential application of the relative subcellular expression of Ep-ICD versus EpEx as prognostic markers for aggressive thyroid cancers.
Aggressive thyroid cancers remain resistant to traditional chemotherapeutic agents.
Furthermore, UHRF1 and ITIH5 have a potential therapeutic/prognostic value for aggressive thyroid tumours.
Moreover, chemotherapeutic treatment proved to be largely ineffective against aggressive thyroid carcinomas [ 8].
The anaplastic (ATC) and aggressive thyroid cancers showed loss of EpEx and increased nuclear and cytoplasmic accumulation of Ep-ICD.
Interestingly, despite the increased prevalence of PTMC, and their aggressive management, thyroid cancer-related mortality has not shown any change over the years.
These results suggest the potential utilisation of dimeric RNases for the therapy of aggressive human thyroid tumours, known to respond poorly to conventional chemotherapeutics.
17 Based on these encouraging data, a phase II trial was performed using axitinib given at a dose of 5 mg twice daily in patients with all types of aggressive incurable thyroid cancer.
FDG PET is also useful in the patient with a neck mass but unknown primary, in patients with aggressive (dedifferentiated) thyroid cancer, and in patients with differentiated cancer where histologic transformation to dedifferentiation is suspected.
The 8505c cell line originates from a patient with undifferentiated highly aggressive anaplastic thyroid cancer harboring mutant p53 [ 28] and a BRAF V600E mutation, resulting in constitutively active MEK-ERK kinase signaling with consequent uncontrolled cell proliferation and tumorigenesis [ 29].
